Biodexa Pharmaceuticals (BDRX) Cash from Operations (2013 - 2022)
Biodexa Pharmaceuticals (BDRX) posted Cash from Operations of 4318519.09 for Q3 2021, up 53.86% sequentially from 9359356.7 in Q4 2020, and up 51.62% YoY from 2848299.4 in Q3 2020.
Biodexa Pharmaceuticals (BDRX) Cash from Operations (2013 - 2022) Analysis & Trends
Biodexa Pharmaceuticals has reported Cash from Operations for 7 years, with the latest figure at 4318519.09 in Q3 2021.
- Quarterly Cash from Operations rose 51.62% year-over-year to 4318519.09 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was 28467846.31 (up 42.96% YoY) and the FY2025 annual result came in at 7371791.29, up 53.16% from the prior year.
- Cash from Operations rose to 4318519.09 in Q3 2021 per BDRX's latest filing, from 9359356.7 in the prior quarter.
- Over five years, Cash from Operations peaked at 4318519.09 in Q3 2021 and troughed at 9359356.7 in Q4 2020.
- A 3-year average of 7116961.58 and a median of 7394985.26 in 2019 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2020 and 2021: Cash from Operations plunged 59.6% in 2020, then surged 51.62% in 2021.
- Over 3 years, Cash from Operations stood at 5864191.29 in 2019, then slumped by 59.6% to 9359356.7 in 2020, then jumped by 53.86% to 4318519.09 in 2021.
- According to Business Quant data, Cash from Operations over the past three periods registered 4318519.09, 9359356.7, and 8925779.23 for Q3 2021, Q4 2020, and Q3 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -4.15 Mn |
| Dec 31, 2022 | -4.15 Mn |
| Sep 17, 2021 | -4.32 Mn |
| Sep 17, 2021 | -4.32 Mn |
| Dec 31, 2020 | -9.36 Mn |
| Dec 31, 2020 | -9.36 Mn |
| Sep 10, 2020 | -8.93 Mn |
| Sep 10, 2020 | -8.93 Mn |
| Dec 31, 2019 | -5.86 Mn |
| Dec 31, 2019 | -5.86 Mn |
| Dec 31, 2016 | -16.27 Mn |
| Dec 31, 2016 | -16.27 Mn |
| Dec 31, 2015 | -18.85 Mn |
| Dec 31, 2015 | -18.85 Mn |
| Dec 31, 2014 | -8.64 Mn |
| Dec 31, 2014 | -8.64 Mn |
| Dec 31, 2013 | -7.18 Mn |
| Dec 31, 2013 | -7.18 Mn |